Acute Myeloid Leukemia: Symptoms, Causes, Survival Rate

Acute myeloid leukemia moves faster than most cancers—symptoms often appear just weeks before diagnosis, and they can mimic a bad flu, making early detection tricky. If you or someone you care about has recently learned about AML, you’re probably trying to make sense of what comes next. This guide walks through the symptoms, causes, survival odds, and treatment timelines using the latest data from Cancer Research UK, the NHS, and other trusted sources.

Most common age: over 65 · Progression type: rapid and aggressive · Annual diagnoses example: fewer than 150 in Ireland · Affected area: bone marrow and blood · Cell origin: myeloid line

These key statistics come from government surveillance data and peer-reviewed cohort studies.

Do people survive AML?

Survival rates for acute myeloid leukemia vary significantly depending on age, overall health, and the specific subtype involved. Understanding these numbers can help patients and families set realistic expectations while navigating treatment decisions.

Survival rates by age and subtype

The five-year survival rate for adults with AML in the United States is 32.9%, according to SEER data from 2015–2021 collected by the National Cancer Institute. This figure represents all adults diagnosed with the disease, regardless of age or subtype.

Age makes a substantial difference. The five-year survival rate drops to around 30% for adults overall, but for people under age 60 diagnosed with AML, the rate rises to 30–40%. Children fare considerably better: the five-year survival rate for those under age 15 is approximately 67%, and for adolescents up to age 19, it reaches 66%, according to Yale Medicine.

Subtype matters significantly. Acute promyelocytic leukemia (APL), a specific subtype, has a remission rate approaching 90% and is often considered curable with targeted treatment. The five-year survival rate for children with APL exceeds 80%.

Factors affecting survival

Cytogenetic testing—analysis of chromosomes in leukemia cells—provides critical information about prognosis. Research from NIH/PMC shows cure rates break down sharply by risk category: 69% for low-risk patients, 24% for intermediate-risk patients (including those with normal karyotypes), and just 6.5% for high-risk patients.

Genetic mutations also play a role. Mutations in the FLT3 gene have historically been associated with a poorer prognosis, although newer targeted therapies are changing this landscape. Patients who respond well to initial treatment generally have better long-term outcomes.

Overall, roughly 50–80% of people with AML achieve complete remission after initial treatment, according to Cleveland Clinic. However, about 50% of those who achieve remission will experience a recurrence of their AML.

What is the main cause of acute myeloid leukemia?

AML doesn’t have a single identifiable cause in most cases. Instead, it develops from a combination of genetic changes that accumulate over a person’s lifetime. Understanding these risk factors helps explain who may be more vulnerable without predicting who will definitely develop the disease.

Risk factors

AML is fundamentally a disease of aging. The condition typically affects people age 60 and older, and the mean age at diagnosis in a large cohort study was 44.1 years. Age remains the strongest risk factor because genetic mutations accumulate over time.

Prior cancer treatment matters. Some people who receive chemotherapy for other cancers have a slightly increased risk of developing AML later. Exposure to high-dose radiation and certain industrial chemicals, particularly benzene, also increases risk.

Genetic predisposition plays a role in some families. While most cases of AML are not inherited, certain inherited syndromes—including Down syndrome, Fanconi anemia, and Bloom syndrome—carry a higher risk.

Genetic changes

At the cellular level, AML develops when DNA mutations occur in the genes that control blood cell development. These mutations cause immature blood cells—normally destined to become healthy white blood cells, red blood cells, or platelets—to multiply uncontrollably instead of maturing properly.

The myeloid line, which normally produces granulocytes and monocytes, becomes corrupted. These defective cells crowd out healthy blood cells, leading to the symptoms patients experience: infections from lack of working white blood cells, anemia from insufficient red blood cells, and easy bruising from low platelet counts.

The implication: Because no single cause dominates, prevention strategies are limited to reducing known environmental exposures rather than eliminating a primary trigger.

What are the early signs of AML?

AML symptoms often develop quickly and can resemble common illnesses, which frequently delays diagnosis. The mean time between first symptoms and actual diagnosis is approximately 55 days, with a median of 30 days, according to research published in NIH/PMC.

Common symptoms

The most prevalent symptom of AML is asthenia, or profound weakness, reported in 69.1% of patients in one study. Fever follows at 51.9%, while pain occurs in 39.8% of cases. Hemorrhagic manifestations—easy bruising, petechiae, ecchymosis, and bleeding from the gastrointestinal tract—affect 46.5% of patients.

Additional symptoms include shortness of breath (dyspnea at 24.5%), pale skin from anemia, frequent infections from compromised white blood cell function, headache, bone and joint pain, tiny red spots on the skin (petechiae), small bumps or rash, vision problems, and abdominal swelling from an enlarged spleen or liver.

Warning signs

Symptoms typically develop and progress rapidly over a few weeks, according to Yale Medicine. This quick onset distinguishes AML from chronic leukemias, which may develop over months or years without obvious symptoms.

In its early stages, AML may resemble the flu—patients commonly experience fever and fatigue. Unlike flu, however, symptoms persist and worsen rather than improving within a week or two.

The pattern: Because early AML mirrors common viral illness, diagnosis often waits until symptoms resist standard treatment or laboratory findings reveal blood abnormalities.

How long does treatment for AML last?

Treatment for AML follows a structured, multi-phase approach that typically spans several months to years. The timeline depends heavily on how the disease responds and whether stem cell transplantation becomes part of the plan.

Treatment phases

AML treatment involves two primary phases. The first, called remission induction therapy, uses intensive chemotherapy to destroy leukemia cells in the blood and bone marrow. The goal is to achieve complete remission—meaning blood counts return to normal and no cancerous cells appear under the microscope when bone marrow is examined.

The second phase, consolidation therapy, begins after remission is achieved. This phase targets any remaining leukemia cells that might not be detectable but could cause a relapse. Consolidation typically involves additional chemotherapy cycles or, in eligible patients, allogeneic stem cell transplantation.

Duration expectations

Induction therapy usually lasts about one month, often requiring hospitalization due to the intensity of chemotherapy and the need to manage side effects like low blood counts. Consolidation therapy adds several more months, with multiple cycles spaced weeks apart.

Currently, allogeneic stem cell transplantation is the only potential cure for AML, according to Cleveland Clinic. Patients who undergo transplantation face a longer process that includes finding a matched donor, pre-transplant conditioning chemotherapy, the transplant procedure itself, and an extended recovery period of months to years.

The implication: The total treatment timeline from diagnosis through possible transplant can extend well beyond a year, with ongoing monitoring lasting for years after.

Is AML one of the worst cancers?

AML ranks among the more aggressive blood cancers, but calling it “the worst” oversimplifies a complex picture. Its severity depends heavily on subtype, patient age, genetic markers, and access to treatment options.

Comparison to other cancers

AML is less common than many solid-tumor cancers but more deadly in percentage terms. The overall five-year survival rate of roughly 33% places it below many early-detected cancers like breast cancer (90%+) or prostate cancer (98%+), but comparable to lung cancer and pancreatic cancer, which are notorious for poor outcomes.

Among blood cancers specifically, AML falls in the middle range. Chronic lymphocytic leukemia (CLL) often progresses slowly over years with a near-normal life expectancy for many patients. Acute lymphoblastic leukemia (ALL) in children has survival rates exceeding 90%, making it far less deadly than AML in pediatric populations.

Terminal aspects

For some patients, AML remains difficult to treat despite modern therapies. Research from NIH/PMC identifies the main causes of death as disease progression (37.72%) and sepsis (31.58%). Bacterial infections account for 32.58% of deaths, hemorrhage for 8.80%, and thrombotic events like heart attack and stroke for 5.36%.

Patients may die before or during treatment in approximately 12% of cases, with 25% dying specifically from disease severity, according to NIH/PMC research. For patients who don’t achieve remission after induction chemotherapy, 59.10% die within five years.

AML presents a stark challenge in modern medicine: it moves quickly, affects primarily older adults who may not tolerate intensive treatment, and until recently had limited targeted options beyond chemotherapy. The survival statistics—roughly one in three adults surviving five years—reflect both the disease’s aggressiveness and the genuine progress made in treatment over the past two decades.